UNCY has 36-month beta value of 2.28. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for UNCY is 87.47M, and currently, short sellers hold a 1.41% ratio of that float. The average trading volume of UNCY on January 16, 2025 was 1.57M shares.
UNCY) stock’s latest price update
The stock of Unicycive Therapeutics Inc (NASDAQ: UNCY) has decreased by -6.30 when compared to last closing price of 0.67. Despite this, the company has experienced a -15.72% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-07 that LOS ALTOS, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that data from the Company’s oxylanthanum carbonate (OLC) Phase 1 dose escalation study in healthy volunteers was published in the peer-reviewed journal, Clinical and Translational Science.
UNCY’s Market Performance
Unicycive Therapeutics Inc (UNCY) has seen a -15.72% fall in stock performance for the week, with a -12.13% decline in the past month and a 56.95% surge in the past quarter. The volatility ratio for the week is 13.49%, and the volatility levels for the past 30 days are at 10.89% for UNCY. The simple moving average for the past 20 days is -13.06% for UNCY’s stock, with a -2.51% simple moving average for the past 200 days.
Analysts’ Opinion of UNCY
Many brokerage firms have already submitted their reports for UNCY stocks, with Piper Sandler repeating the rating for UNCY by listing it as a “Overweight.” The predicted price for UNCY in the upcoming period, according to Piper Sandler is $9 based on the research report published on April 04, 2024 of the previous year 2024.
UNCY Trading at -3.58% from the 50-Day Moving Average
After a stumble in the market that brought UNCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.47% of loss for the given period.
Volatility was left at 10.89%, however, over the last 30 days, the volatility rate increased by 13.49%, as shares sank -10.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.97% upper at present.
During the last 5 trading sessions, UNCY fell by -15.42%, which changed the moving average for the period of 200-days by -55.32% in comparison to the 20-day moving average, which settled at $0.7222. In addition, Unicycive Therapeutics Inc saw -20.95% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for UNCY
Current profitability levels for the company are sitting at:
- 107.63 for the present operating margin
- 2.35 for the gross margin
The net margin for Unicycive Therapeutics Inc stands at 106.74. The total capital return value is set at -1.04. Equity return is now at value -185.19, with -99.72 for asset returns.
Based on Unicycive Therapeutics Inc (UNCY), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -32.8. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -416.7.
Currently, EBITDA for the company is -30.18 million with net debt to EBITDA at 0.79. When we switch over and look at the enterprise to sales, we see a ratio of -124.91. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.61.
Conclusion
To put it simply, Unicycive Therapeutics Inc (UNCY) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
